- Home
- BDL vs MREO Comparison
BDL vs MREO Comparison
Compare BDL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDL | MREO |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 52.5M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BDL | MREO |
|---|---|---|
| Price | $30.50 | $0.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.2K | ★ 1.8M |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 49.72 | 16.67 |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $205,248,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $15.40 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $22.61 | $0.20 |
| 52 Week High | $35.98 | $2.94 |
Technical Indicators
Market Signals| Indicator | BDL | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 36.04 |
| Support Level | $28.82 | $0.21 |
| Resistance Level | $33.69 | $0.36 |
| Average True Range (ATR) | 1.46 | 0.03 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 29.29 | 37.85 |
Price Performance
Historical ComparisonAbout BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).